Amplifold

Based in Martinsried, Germany, Amplifold develops rapid in vitro diagnostic tests utilizing DNA origami nanotechnology to amplify molecular signals in lateral flow assays. The company's proprietary diagnostic platform increases test sensitivity up to 100-fold compared to conventional methods, enabling central lab accuracy in point-of-care healthcare settings while keeping manufacturing costs low. Amplifold recently closed an oversubscribed €5 million seed funding round to industrialize its production workflows, expand product development, and pursue European IVDR regulatory certification. The biotechnology startup is backed by a syndicate of prominent venture capital investors, including Y Combinator, Matterwave Ventures, XISTA Science Ventures, Bayern Kapital, and b2venture. Operating out of the Innovation and Start-up Center for Biotechnology, the enterprise was spun out of the Ludwig Maximilian University of Munich and founded in 2023 by Dr. Maximilian Urban and Dr. Enzo Kopperger.